Your browser doesn't support javascript.
loading
CD4+ T cells are homeostatic regulators during Mtb reinfection.
Bromley, Joshua D; Ganchua, Sharie Keanne C; Nyquist, Sarah K; Maiello, Pauline; Chao, Michael; Borish, H Jacob; Rodgers, Mark; Tomko, Jaime; Kracinovsky, Kara; Mugahid, Douaa; Nguyen, Son; Wang, Dennis; Rosenberg, Jacob M; Klein, Edwin C; Gideon, Hannah P; Floyd-O'Sullivan, Roisin; Berger, Bonnie; Scanga, Charles A; Lin, Philana Ling; Fortune, Sarah M; Shalek, Alex K; Flynn, JoAnne L.
Afiliación
  • Bromley JD; Ragon Institute of MGH, MIT, and Harvard, Cambridge, MA, USA.
  • Ganchua SKC; Institute for Medical Engineering and Science (IMES), Massachusetts Institute of Technology, Cambridge, MA, USA.
  • Nyquist SK; Broad Institute of MIT and Harvard, Cambridge, MA, USA.
  • Maiello P; Graduate Program in Microbiology, Massachusetts Institute of Technology, Cambridge, MA, USA.
  • Chao M; Department of Microbiology and Molecular Genetics, University of Pittsburgh School of Medicine, Pittsburgh PA USA.
  • Borish HJ; Center for Vaccine Research, University of Pittsburgh, Pittsburgh PA USA.
  • Rodgers M; Ragon Institute of MGH, MIT, and Harvard, Cambridge, MA, USA.
  • Tomko J; Institute for Medical Engineering and Science (IMES), Massachusetts Institute of Technology, Cambridge, MA, USA.
  • Kracinovsky K; Broad Institute of MIT and Harvard, Cambridge, MA, USA.
  • Mugahid D; Computer Science and Artificial Intelligence Laboratory, Massachusetts Institute of Technology, Cambridge, MA, USA.
  • Nguyen S; Department of Microbiology and Molecular Genetics, University of Pittsburgh School of Medicine, Pittsburgh PA USA.
  • Wang D; Ragon Institute of MGH, MIT, and Harvard, Cambridge, MA, USA.
  • Rosenberg JM; Department of Immunology and Infectious Diseases, Harvard T.H. Chan School of Public Health, Boston, MA, USA.
  • Klein EC; Department of Microbiology and Molecular Genetics, University of Pittsburgh School of Medicine, Pittsburgh PA USA.
  • Gideon HP; Center for Vaccine Research, University of Pittsburgh, Pittsburgh PA USA.
  • Floyd-O'Sullivan R; Department of Microbiology and Molecular Genetics, University of Pittsburgh School of Medicine, Pittsburgh PA USA.
  • Berger B; Center for Vaccine Research, University of Pittsburgh, Pittsburgh PA USA.
  • Scanga CA; Department of Microbiology and Molecular Genetics, University of Pittsburgh School of Medicine, Pittsburgh PA USA.
  • Lin PL; Center for Vaccine Research, University of Pittsburgh, Pittsburgh PA USA.
  • Fortune SM; Department of Microbiology and Molecular Genetics, University of Pittsburgh School of Medicine, Pittsburgh PA USA.
  • Shalek AK; Center for Vaccine Research, University of Pittsburgh, Pittsburgh PA USA.
  • Flynn JL; Ragon Institute of MGH, MIT, and Harvard, Cambridge, MA, USA.
bioRxiv ; 2023 Dec 21.
Article en En | MEDLINE | ID: mdl-38187598
ABSTRACT
Immunological priming - either in the context of prior infection or vaccination - elicits protective responses against subsequent Mycobacterium tuberculosis (Mtb) infection. However, the changes that occur in the lung cellular milieu post-primary Mtb infection and their contributions to protection upon reinfection remain poorly understood. Here, using clinical and microbiological endpoints in a non-human primate reinfection model, we demonstrate that prior Mtb infection elicits a long-lasting protective response against subsequent Mtb exposure and that the depletion of CD4+ T cells prior to Mtb rechallenge significantly abrogates this protection. Leveraging microbiologic, PET-CT, flow cytometric, and single-cell RNA-seq data from primary infection, reinfection, and reinfection-CD4+ T cell depleted granulomas, we identify differential cellular and microbial features of control. The data collectively demonstrate that the presence of CD4+ T cells in the setting of reinfection results in a reduced inflammatory lung milieu characterized by reprogrammed CD8+ T cell activity, reduced neutrophilia, and blunted type-1 immune signaling among myeloid cells, mitigating Mtb disease severity. These results open avenues for developing vaccines and therapeutics that not only target CD4+ and CD8+ T cells, but also modulate innate immune cells to limit Mtb disease.

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Idioma: En Revista: BioRxiv Año: 2023 Tipo del documento: Article País de afiliación: Estados Unidos

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Idioma: En Revista: BioRxiv Año: 2023 Tipo del documento: Article País de afiliación: Estados Unidos